Compare Crispr Therapeutics AG (CRSP) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Valero Energy Corporation — how do they compare? Crispr Therapeutics AG trades at $53.78 (market cap $5.22B), while Valero Energy Corporation trades at $333.03 (market cap $95.08B). The key difference: Valero Energy Corporation is far larger — about 18.2× Crispr Therapeutics AG's market cap, and Valero Energy Corporation pays a 1.45% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | VLO | |
|---|---|---|
Market Cap | $5.22B | $95.08B |
Sector | Health | Energy |
52-Week High | $76.78 | $330.21 |
52-Week Low | $44.34 | $135.82 |
Enterprise Value | $3.64B | $98.55B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Valero Energy (VLO) trades at $329.99, up 4.78% on the day, reflecting strong momentum after recent earnings beats. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals indicate robust profitability with a 29.31% ROE and a P/E of 13.51. Recent news highlights refining strength and geopolitical factors benefiting the sector.
Outlook remains positive with analyst consensus favoring a Buy rating and a $324.27 price target. Key risks include volatile oil prices and refining margin pressures, but disciplined capital allocation and renewable diesel growth offer upside potential for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
